CytomX Therapeutics Inc
CTMX
NASDAQ
Biotechnology
$3.36
USD
+0.01 (+0.30%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $738.68M
Volume 1.4M
Revenue
$18.30M
TTM
-87.0%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-79.65M
TTM
-266.0%
YoY
Operating Cash Flow
$-82.41M
TTM
-6.4%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 18.7 | 6.0 | 0.7 | 10.3 | 1.4 |
YoY Growth | -25.7% | -82.2% | -98.3% | -79.9% | -92.4% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 18.7 | 6.0 | 0.7 | 10.3 | 1.4 |
Selling, General & Administrative | 6.6 | 6.4 | 7.4 | 10.7 | 7.6 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 19.9 | 21.7 | 28.6 | 29.9 | 25.2 |
Operating Income | -1.3 | -15.8 | -27.9 | -19.7 | -23.8 |
EBITDA | -0.9 | -15.6 | -27.4 | -19.4 | -23.7 |
Other Income / Expense | 0.0 | 0.0 | -0.0 | -0.0 | 0.0 |
Total Other Income / Expense | 1.2 | 1.6 | 1.5 | 1.5 | 3.2 |
Income Before Income Taxes | -0.1 | -14.2 | -26.5 | -18.2 | -20.6 |
Income Taxes | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
Net Income | -0.2 | -14.2 | -26.5 | -18.2 | -20.7 |
Consolidated Net Income / Loss | -0.2 | -14.2 | -26.5 | -18.2 | -20.7 |
Net Income Attributable to Common Shareholders | -0.2 | -14.2 | -29.5 | -18.2 | -20.7 |
Basic EPS | $0.00 | -$0.09 | -$0.17 | -$0.10 | -$0.09 |
Diluted EPS | $0.00 | -$0.09 | -$0.17 | -$0.10 | -$0.09 |
Basic Shares Outstanding | 129.1M | 165.0M | 170.5M | 177.3M | 218.9M |
Diluted Shares Outstanding | 129.1M | 165.0M | 170.5M | 177.3M | 218.9M |